Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are up during Friday's premarket session as the company recently reported its fourth-quarter and full-year financial results, highlighting significant developments in its product pipeline.
Tonix Pharmaceuticals appoints industry veteran Ganesh Kamath as Head of Market Access
Tonix Pharmaceuticals (NASDAQ:TNXP) announced the appointment of Ganesh Kamath as its head of market access, effective September 29, 2025. The biotechnology company said Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix.
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valuation, potential dilution, and uncertainty around commercialization and pricing. Tonmya's novel formulation and high unmet need could drive strong adoption, with revenue potential of $219M–$365M annually at modest market penetration.
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy
I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved market; FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue. Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage in this market.
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?
Tonix Pharmaceuticals' TNX-102 SL shows a high probability of FDA approval for fibromyalgia, supported by positive Phase 3 trials and an acceptable safety profile. A recent $500M shelf offering caused a stock dip but does not impact approval odds; current valuation does not include TNX-102 approval. Risks include modest efficacy and challenging market adoption; therefore, we recommend buying TNXP stock before PDUFA and reassessing before commercial launch.
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years
PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Committee Meeting of TNX-102 SL for the treatment of patients with Fibromyalgia. TNX-102 SL met primary endpoints in two Phase 3 studies, showing significant pain reduction, positioning it as the first new Fibromyalgia drug in 15 years.
Pharma Frenzy: Volatility Ignites Biotech Sector
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals NASDAQ: TNXP and Lexeo Therapeutics NASDAQ: LXEO. The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions.
Is Tonix Pharmaceuticals the Next Biotech Breakout?
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals NASDAQ: TNXP is gaining significant attention from investors and market participants. The company develops therapies for conditions with high unmet needs, with a focus on pain management, CNS disorders, and public health vaccines.
